Development of the survey
This is a prospective observational study using a survey distributed to all Pediatric Hematology-Oncology physicians and subspecialty residents in Canada from February-October 2020. Authors developed a survey that consists of 19 multiple choice questions (see Supporting Information) 3 questions collect demographic information, 10 questions address the use and interpretation of asparaginase levels and 6 questions address the respondents’ clinical experience with hypersensitivity reactions and modifying asparaginase formulations. A table defining the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 [4] was included in the survey for reference.
For 11 questions, respondents were asked to select one answer. For the remaining 8 questions, respondents were asked to select all answers that applied (see Supporting Information).